)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Aptahem
Aptahem (APTA) investor relations material
Aptahem Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Focused on advancing Apta-1 through strategic development and cost discipline amid a challenging financing climate.
Strengthened manufacturing platform with improved purity and efficiency for Apta-1, supporting future clinical development and partnerships.
Entered a commercial partnership agreement with Jarlen Capital for out-licensing opportunities post-period.
Financial highlights
Operating income for Q2 2026 was 342 KSEK, down from 816 KSEK year-over-year; H1 2026 was 916 KSEK, down from 1,453 KSEK.
Result after financial items for Q2 2026 was -1,351 KSEK (vs. -1,368 KSEK); H1 2026 was -2,743 KSEK (vs. -3,398 KSEK).
Earnings per share for Q2 2026 was -0.05 SEK (vs. -0.08 SEK); H1 2026 was -0.11 SEK (vs. -0.20 SEK).
Cash and cash equivalents at June 30, 2026, were 1,722 KSEK (vs. 1,781 KSEK).
Equity ratio at June 30, 2026, was 98.66% (vs. 97.82%).
Outlook and guidance
Continued focus on cost control and prioritizing value-creating activities for Apta-1.
Actively seeking phase 2 collaborations with academic institutions for targeted studies in sepsis and related conditions.
Strategy remains to advance Apta-1 toward patient studies and commercialization through clinical development, external validation, and strategic partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aptahem
- Improved Q1 results, strengthened finances, and strategic advances for Apta-1 development.APTA
Q1 2026 - Strategic progress, improved results, and new capital define a pivotal year for clinical development.APTAQ4 2025
- Advanced US listing plans, strengthened IP, and raised 6 MSEK amid ongoing net losses.APTAQ3 2025
- Advancing a novel sepsis therapy, U.S. listing, and global engagement via investor webinar.APTAStatus Update
- U.S. listing preparations advance with regulatory, financial, and IP initiatives plus stakeholder updates.APTAStatus Update
- Improved financials, strategic partnerships, and U.S. listing plans drive next growth phase.APTAQ2 2025
- Lower revenue, improved net loss, and new capital support Apta-1's clinical progress.APTAQ3 2024
- Phase 1 for Apta-1 completed; phase 2 prep, rights issue, and reverse split executed.APTAQ2 2024
- Q1 2025 saw reduced losses, strategic advances, and a planned rights issue for Aptahem.APTAQ1 2025
Next Aptahem earnings date
Q3 202627 Nov, 2026
Aptahem
Next Aptahem earnings date
Q3 202627 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage